A. Green

发表

A gene-expression signature to predict survival in breast cancer across independent data sets

I. Ellis, C. Caldas, S. Aparicio, 2007, Oncogene.

The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer

G. Ball, I. Ellis, C. Caldas, 2010, Breast Cancer Research and Treatment.

DNA Damage–Induced Bcl-xL Deamidation Is Mediated by NHE-1 Antiport Regulated Intracellular pH

A. Green, R. Zhao, D. Oxley, 2006, PLoS biology.

SC3 - consensus clustering of single-cell RNA-Seq data

M. Schaub, Mauricio Barahona, M. Hemberg, 2016, Nature Methods.

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer

G. Ball, I. Ellis, J. Garibaldi, 2014, British Journal of Cancer.

Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development

N. Carter, Fengtang Yang, M. Stratton, 2011, Cell.

Patterns of somatic mutation in human cancer genomes

E. Birney, A. Nicholson, M. Stratton, 2007, Nature.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

P. Campbell, A. Green, G. Vassiliou, 2005, The Lancet.

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations

A. Green, A. Bench, N. Cross, 2013, British journal of haematology.

Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic Regulators

W. Ouwehand, B. Göttgens, N. Wilson, 2011, Developmental cell.

International network of cancer genome projects

Gary D Bader, Benjamin J. Raphael, Joshua M. Stuart, 2010, Nature.

Population dynamics of normal human blood inferred from somatic mutations

Peter J. Campbell, Michael R. Stratton, Inigo Martincorena, 2018, Nature.

Pan-cancer analysis of whole genomes

Steven J. M. Jones, Nuno A. Fonseca, Icgc, 2020, Nature.

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

M. Stratton, P. Campbell, P. Stephens, 2011, The New England journal of medicine.

Inactivating CUX1 mutations promote tumorigenesis

P. Campbell, A. Rust, K. Döhner, 2013, Nature Genetics.

Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing

M. Stratton, P. Campbell, P. Stephens, 2008, Proceedings of the National Academy of Sciences.

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

Andrew J. Bannister, B. Göttgens, A. Green, 2009, Nature.

ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling.

H. Lodish, B. Göttgens, A. Green, 2009, Blood.

Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.

M. Leversha, A. Green, J. Chang, 2000, Blood.

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

M. Stratton, P. Futreal, H. Lodish, 2007, The New England journal of medicine.

Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors

B. Göttgens, A. Green, S. Kinston, 2002, The EMBO journal.

The scl +18/19 Stem Cell Enhancer Is Not Required for Hematopoiesis: Identification of a 5′ Bifunctional Hematopoietic-Endothelial Enhancer Bound by Fli-1 and Elf-1

B. Göttgens, A. Green, C. Begley, 2004, Molecular and Cellular Biology.

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer

Andrew D. Yates, Yvonne R Stephens, A. Nicholson, 2005, Nature Genetics.

Somatic mutations of the protein kinase gene family in human lung cancer.

Andrew D. Yates, Yvonne R Stephens, A. Nicholson, 2005, Cancer research.

The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation.

M. Tymms, I. Kola, A. Green, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

M. Stratton, P. Campbell, S. O'meara, 2013, Blood.

Long-range comparison of human and mouse SCL loci: localized regions of sensitivity to restriction endonucleases correspond precisely with peaks of conserved noncoding sequences.

D R Bentley, D. Grafham, D. Bentley, 2001, Genome research.

Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts

I. Ellis, D. Soria, A. Green, 2013, British Journal of Cancer.

The Philadelphia translocation and pre‐existing myeloproliferative disorders

P. Campbell, A. Green, N. Curtin, 2005, British journal of haematology.

A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks

G. Ball, I. Ellis, R. Rees, 2010, Breast Cancer Research and Treatment.

The myeloproliferative disorders.

P. Campbell, A. Green, 2006, The New England journal of medicine.

Order Matters: The Order of Somatic Mutations Influences Cancer Evolution.

David G Kent, Anthony R Green, D. Kent, 2017, Cold Spring Harbor perspectives in medicine.

Effect of mutation order on myeloproliferative neoplasms.

Paola Guglielmelli, George S Vassiliou, Beatriz Bellosillo, 2015, The New England journal of medicine.

Janus kinase deregulation in leukemia and lymphoma.

Anthony R Green, Edwin Chen, L. Staudt, 2012, Immunity.

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

G. Wainreb, A. Green, A. Borkhardt, 2008, The Lancet.

Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.

A. Green, D. Oscier, M. McMullin, 2008, Blood.

Neuroregulators and psychiatric disorders by E. Usdin, D. A. Hamburg and J. D. Barchas (eds.), 658 pages, Oxford University Press, London, 1977, £ 25.50

A. Green, 1978, Journal of the Neurological Sciences.

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.

P. Campbell, A. Green, W. Erber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative analysis of G-banding, chromosome painting, locus-specific fluorescence in situ hybridization, and comparative genomic hybridization in chronic myeloid leukemia blast crisis.

S. Gribble, A. Green, P. Sinclair, 1999, Cancer genetics and cytogenetics.

Temporal regulation of Cre‐recombinase activity in Scl‐positive neurons of the central nervous system

B. Göttgens, A. Green, C. Begley, 2007, Genesis.

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.

Peter J Campbell, Wendy N Erber, Keith Wheatley, 2008, Blood.

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort.

P. Campbell, A. Green, C. Harrison, 2012, Blood.

How I treat essential thrombocythemia.

P. Campbell, A. Green, W. Erber, 2011, Blood.

How I treat How I treat essential thrombocythemia

P. Campbell, A. Green, W. Erber, 2011 .

Guideline for investigation and management of adults and children presenting with a thrombocytosis

P. Campbell, A. Green, W. Erber, 2010, British journal of haematology.

Reply to K.N. Naresh

P. Campbell, A. Green, W. Erber, 2009 .

Reply to J. Thiele et al

P. Campbell, A. Green, W. Erber, 2009 .

Pathogenesis and management of essential thrombocythemia.

A. Green, P. Beer, 2009, Hematology. American Society of Hematology. Education Program.

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

P. Campbell, R. Bowman, A. Green, 2008, Blood.

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

P. Campbell, A. Green, L. Scott, 2006, Blood.

The stem/progenitor landscape is reshaped in a mouse model of essential thrombocythemia and causes excess megakaryocyte production

B. Göttgens, A. Green, M. Vacca, 2020, Science Advances.

Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program

F. Hamey, B. Göttgens, Alice Giustacchini, 2017, The Journal of experimental medicine.

of the haemangioblast in zebrafish The transcription factors, Scl and Lmo2, act together during development

A. Green, C. Verfaillie, M. Gering, 2013 .

The SCL +40 Enhancer Targets the Midbrain Together with Primitive and Definitive Hematopoiesis and Is Regulated by SCL and GATA Proteins

B. Göttgens, A. Green, J. Bowen, 2007, Molecular and Cellular Biology.

The stem cell leukaemia (SCL) gene: a critical regulator of haemopoietic and vascular development.

B. Göttgens, A. Green, B. Göttgens, 1999, The international journal of biochemistry & cell biology.

The pufferfish SLP-1 gene, a new member of the SCL/TAL-1 family of transcription factors.

D. Bentley, G. Elgar, S. Aparício, 1998, Genomics.

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

M. Malumbres, A. Green, C. Bock, 2013, Cancer cell.

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.

A. Green, R. Clark, G. Vassiliou, 2003, Blood.

The SCL transcriptional network and BMP signaling pathway interact to regulate RUNX1 activity

B. Göttgens, A. Green, J. Landry, 2007, Proceedings of the National Academy of Sciences.

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders

P. Campbell, A. Green, J. Reilly, 2008, Haematologica.

CUTANEOUS VASCULITIS IN PATIENTS WITH MYELODYSPLASIA

D. P. Bentley, A. Green, D. Bowen, 1990, British journal of haematology.

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders

A. Green, M. Dawson, M. Scott, 2010, British journal of haematology.

Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.

A. Green, P. Beer, 2010, The New England journal of medicine.

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

M. Cazzola, C. Pascutto, T. Haferlach, 2011, Blood.

Molecular characterization of NSCL, a gene encoding a helix-loop-helix protein expressed in the developing nervous system.

A. Green, C. Begley, S. Lipkowitz, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Thrombopoietin signaling to chromatin elicits rapid and pervasive epigenome remodeling within poised chromatin architectures

A. Green, P. Fraser, S. Schoenfelder, 2017, bioRxiv.

Thrombopoietin signaling to chromatin elicits rapid and pervasive epigenome remodeling within poised chromatin architectures

A. Green, P. Fraser, S. Schoenfelder, 2017, bioRxiv.

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.

L. Campbell, A. Green, A. Bench, 2002, Blood.

Kidney, blood, and endothelium: developmental expression of stem cell leukemia during nephrogenesis.

A. Green, N. Amariglio, S. Izraeli, 2004, Kidney international.

Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification

I. Ellis, A. Green, E. Rakha, 2015, Breast Cancer Research and Treatment.

Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia

P. Futreal, R. Wooster, P. Campbell, 2005 .

Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

Bin Tean Teh, Andrew Menzies, Keiran Raine, 2014, eLife.

Mutant Calreticulin in the Myeloproliferative Neoplasms

A. Green, T. Klampfl, J. Grinfeld, 2020, HemaSphere.

Myeloproliferative neoplasms

A. Green, A. Bench, A. Godfrey, 2019, Molecular Hematology 4e.

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage.

D. Kent, O. Dovey, A. Green, 2018, Blood.

RECQL 5 Suppresses Onco genic JAK 2-Induced Replication Stress and Genomic Instability Graphical

A. Green, D. DeAngelo, A. Godfrey, 2015 .

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

A. Green, D. DeAngelo, A. Godfrey, 2015, Cell reports.

JAK 2 V 617 F-homozygosity drives a phenotypic switch between myeloproliferative neoplasms in a murine model , but is insufficient to sustain clonal expansion *

D. Kent, A. Green, P. Liu, 2014 .

reactivity in a knock-in mouse model of essential thrombocythemia JAK2V617F leads to intrinsic changes in platelet formation and

A. Green, N. Soranzo, L. Vasquez, 2014 .

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

D. Kent, A. Green, A. Godfrey, 2014, Blood.

JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.

A. Green, N. Soranzo, S. Watson, 2013, Blood.

exon 12 mutations JAK2 associated with Molecular and clinical features of the myeloproliferative neoplasm

M. Cazzola, C. Pascutto, T. Haferlach, 2013 .

Methods for detecting mutations in the human JAK2 gene.

A. Green, E. Baxter, A. Bench, 2013, Methods in molecular biology.

reliability and utility for identifying disease subtypes Bone marrow pathology in essential thrombocythemia: interobserver

P. Campbell, A. Green, W. Erber, 2013 .

Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion

D. Kent, A. Green, K. Kirschner, 2013, PLoS biology.

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

P. Campbell, K. Döhner, A. Green, 2012, Blood.

Genotype-phenotype interactions in the myeloproliferative neoplasms.

A. Green, A. Godfrey, 2012, Hematology/oncology clinics of North America.

Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.

A. Green, B. Huntly, E. Gudgin, 2011, Blood.

Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.

A. Green, W. Erber, A. Bench, 2011, Blood.

Mouse models of myeloproliferative neoplasms: JAK of all grades

D. Kent, A. Green, E. Chen, 2011, Disease Models & Mechanisms.

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

R. Kusec, A. Green, W. Vainchenker, 2010, Blood.

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.

P. Campbell, A. Green, P. Liu, 2010, Blood.

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

E. Dermitzakis, P. Campbell, C. Ingle, 2010, Cancer cell.

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis

A. Green, W. Erber, A. Bench, 2010, British journal of haematology.

studies, cytogenetic associations, and role in leukemic transformation in the myeloproliferative disorders: timing, clonality JAK2 Mutation of

P. Campbell, R. Kusec, A. Green, 2010 .

SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases

J. Johnston, S. Constantinescu, A. Green, 2009, Haematologica.

Mutations of JAK 2 in acute lymphoblastic leukaemias associated with Down ’ s syndrome

G. Wainreb, A. Green, A. Borkhardt, 2008 .

Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis

A. Green, L. Scott, A. Jones, 2008, Haematologica.

Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis

P. Campbell, A. Green, J. Reilly, 2007, British journal of haematology.

The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels

A. Green, W. Erber, J. Reilly, 2007, Haematologica.

Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.

P. Campbell, A. Green, W. Erber, 2006, Methods in molecular medicine.

Mechanisms of Disease The Myeloproliferative Disorders

P. Campbell, A. Green, F. Path, 2006 .

The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis.

A. Green, J. Reilly, M. McMullin, 2006, Haematologica.

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.

M. Stratton, P. Futreal, R. Wooster, 2005, Blood.

SOCS 3 tyrosine phosphorylation as a potential biomarker for myeloproliferative neoplasms associated with mutant JAK 2 kinases

J. Johnston, S. Constantinescu, A. Green, 2022 .

The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization

A. Green, A. Gruszka-Westwood, M. McMullin, 2000, British journal of haematology.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Paola Guglielmelli, Torsten Haferlach, William Tapper, 2015, Nature Communications.

STAT1 activation in association with JAK2 exon 12 mutations

K. Döhner, A. Green, J. Reilly, 2016, Haematologica.

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis.

H. Heimpel, M. Griesshammer, A. Green, 2003, Blood.

Phylogenetic reconstruction of myeloproliferative neoplasm reveals very early origins and lifelong evolution

P. Campbell, A. Menzies, A. Green, 2020, bioRxiv.

GATA factors yet Lyl 1 cannot rescue the early SCL The paralogous haemopoietic regulators Lyl 1 and SCL

Landry, V. Kouskoff, F. Sablitzky, 2006 .

do not contribute to tumor endothelium Genetically tagging endothelial cells in vivo: bone marrow-derived cells

A. Green, U. Schmidt, M. V. Eekelen, 2013 .

Hemostasis, Thrombosis, and Vascular Biology Materials and Methods Lacz and Platelet Endothelial Cell Adhesion Molecule 1 (pecam-1) Staining

Mark A. Hall, B. Göttgens, A. Green, 2022 .

L3mbtl, the mouse orthologue of the imprinted L3MBTL, displays a complex pattern of alternative splicing and escapes genomic imprinting.

A. Green, A. Ferguson-Smith, G. Vassiliou, 2005, Genomics.

Patterns of somatic mutation in human cancer genomes

E. Birney, A. Nicholson, M. Stratton, 2007, Nature.

Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.

A. Green, A. Bench, B. Huntly, 2003, Blood.

chromosome 9 in chronic myeloid leukemia Double jeopardy from a single translocation : deletions of the derivative

A. Green, A. Bench, B. Huntly, 2003 .

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response

I. Ellis, E. Rakha, A. Green, 2015, British Journal of Cancer.

Phylogenetic reconstruction of adult blood cancer reveals early origins and lifelong evolution.

P. Campbell, A. Menzies, A. Green, 2020 .

Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes

A. Green, K. Champion, J. Gilbert, 1997, British journal of haematology.

A novel mode of enhancer evolution: the Tal1 stem cell enhancer recruited a MIR element to specifically boost its activity.

B. Göttgens, A. Green, G. Follows, 2008, Genome research.

Fluorescence in situ hybridization detection of two telomeres on the short arm of a derived chromosome 16 in an infant with thrombocytopenia.

S. Gribble, A. Green, D. Williams, 2000, Cancer genetics and cytogenetics.

Analysis of Jak2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation.

A. Green, K. Ottersbach, S. Fitch, 2016, Blood.

SCL is coexpressed with GATA-1 in hemopoietic cells but is also expressed in developing brain.

J. Visvader, A. Green, T. Lints, 1992, Oncogene.

A. Green, C. Begley, 1992, International journal of cell cloning.

An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors.

B. Göttgens, A. Green, C. Begley, 1999, Development.

Constitutive expression of the putative transcription factor SCL associated with proviral insertion in the myeloid leukemic cell line WEHI-3BD-.

A. Green, C. Begley, L. Robb, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Deletion of the Scl +19 enhancer increases the blood stem cell compartment without affecting the formation of mature blood lineages

B. Göttgens, A. Green, L. Scott, 2012, Experimental hematology.

The neuropharmacology of depression.

A. Green, 1978, Scottish medical journal.

Induced myeloid differentiation of K562 cells with downregulation of erythroid and megakaryocytic transcription factors: a novel experimental model for hemopoietic lineage restriction.

A. Green, C. Begley, E. DeLuca, 1993, Experimental hematology.

Diverse mutational landscapes in human lymphocytes

P. Campbell, Mairi S. Shepherd, E. Laurenti, 2022, Nature.

The pathogenesis and management of essential thrombocythaemia.

A. Green, 1999, Haematologica.

Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells.

A. Green, N. White, E. Nacheva, 1994, Blood.

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

A. Mead, A. Green, R. Mesa, 2014, British journal of haematology.

JAK2 exon 12 mutations occur frequently in idiopathic erythrocytosis patients with low serum erythropoietin levels

A. Green, W. Erber, J. Reilly, 2007 .

sustain clonal expansion myeloproliferative neoplasms in a murine model , but is insufficient to-homozygosity drives a phenotypic switch between JAK 2 V 617

D. Kent, A. Green, A. Godfrey, 2014 .

Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera

A. Green, W. Erber, L. Scott, 2007, British journal of haematology.

Myeloproliferative neoplasms

A. Green, A. Bench, A. Godfrey, 2018, Molecular Hematology 4e.

CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum

A. Green, P. Guglielmelli, A. Vannucchi, 2014, American journal of hematology.

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

P. Campbell, A. Green, A. Godfrey, 2013, Haematologica.

Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis.

D. Kent, A. Green, E. Baxter, 2021, Blood advances.

Mutant CALR functions: gains and losses.

A. Green, Daniel Prins, 2020, Blood.

The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients.

A. Green, R. Hannah, B. Göttgens, 2015, Blood.

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling

A. Green, H. Quentmeier, A. Bench, 2014, Leukemia.

Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia

P. Campbell, A. Mead, A. Green, 2014, British journal of haematology.

DELETIONS OF CHROMOSOME 20q AND THE PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS

A. Green, F. A. Aimakopoulos, F. A. Aimakopoulos, 1996, British journal of haematology.

Appropriate and inappropriate neuroendocrine products in pulmonary tumourlets.

A. Green, J. Gosney, W. Taylor, 1990, Thorax.

Does the P 2 X 1 del variant lacking 17 amino acids in its extracellular domain represent a relevant functional ion channel in platelets ?

L. Campbell, A. Green, D. Niederwieser, 2002 .

Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing Scl under the control of a stem cell enhancer.

A. Green, L. Gambardella, M. Sánchez, 2001, Development.

Three Distinct Patterns of Histone H3Y41 Phosphorylation Mark Active Genes

Andrew J. Bannister, S. Robson, B. Göttgens, 2012, Cell reports.

Cytogenetics of Myeloproliferative Disorders

A. Green, A. Bench, B. Huntly, 2004 .

Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.

S. le Cessie, A. Green, J. Falkenburg, 2004, Blood.

High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic

M. Stratton, P. Campbell, M. Cazzola, 2012 .

Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes

A. Green, N. White, E. Nacheva, 1994 .

Abnormalities of the long arm of chromosome 20 in myeloid malignancies

T. L. Hood, A. Green, S. Swanton, 1999 .

Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes.

N. Carter, A. Green, N. White, 1995, Cancer genetics and cytogenetics.

Antisense SCL suppresses self‐renewal and enhances spontaneous erythroid differentiation of the human leukaemic cell line K562.

A. Green, C. Begley, E. DeLuca, 1991, The EMBO journal.

Response: essential thrombocythemia: seeing the wood for the trees

P. Campbell, A. Green, W. Erber, 2011 .

Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia.

P. Campbell, A. Green, E. Baxter, 2006, Haematologica.

Diagnostic pathway for the investigation of thrombocytosis

P. Campbell, A. Green, J. Reilly, 2013, British journal of haematology.

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features

P. Campbell, A. Green, A. Godfrey, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival implications of molecular heterogeneity in variant Philadelphia‐positive chronic myeloid leukaemia

A. Green, B. Huntly, A. Reid, 2003, British journal of haematology.

Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system.

A. Green, P. Sinclair, E. Nacheva, 1997, Blood.

PEPTIDE REGULATORY FACTORS: MULTIFUNCTIONAL MEDIATORS OF CELLULAR GROWTH AND DIFFERENTIATION

A. Green, 1989, The Lancet.

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms

K. Döhner, A. Green, P. Möller, 2010, Haematologica.

Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies.

A. Green, A. Ferguson-Smith, G. Vassiliou, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Fusion of rous‐sarcoma‐virus‐transformed rat cells to morphologically normal human or rat cells results in transcriptional suppression of the provirus that depends on its chromosomal integration site

A. Green, S. Povey, J. Wyke, 1990, International journal of cancer.

Clinical and biochemical effects of parachlorophenylalanine in a patient with the carcinoid syndrome

H. F. Woods, A. Green, A. Boulton, 1982, Postgraduate medical journal.

Antidepressants: neurochemical, behavioural and clinical perspectives S.J. Enna J.B.

A. Green, 1982, Neuroscience.

Thrombin receptor expression and function in large granular lymphocyte proliferative disorders

A. Green, M. Macey, A. Murrell, 1994, British journal of haematology.

Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia.

P. Campbell, A. Green, P. Beer, 2010, Blood.

MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling

A. Green, A. Godfrey, F. Comoglio, 2018, Leukemia.

Double Philadelphia masquerading as chromosome 20q deletion – a new recurrent abnormality in chronic myeloid leukaemia blast crisis

L. Campbell, A. Green, S. Swanton, 2003, British journal of haematology.

The Stem Cell Leukaemia Gene: A Critical Regulator of Haemopoiesis Vasculogenesis

A. Green, 2003 .

Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements

B. Göttgens, A. Elefanty, A. Green, 1997, Oncogene.

Absence of SCL mutations in myeloid malignancies

W. Hiddemann, A. Green, S. Schnittger, 2003, British journal of haematology.

Directing oncogenic fusion genes into stem cells via an SCL enhancer.

M. Eguchi, A. Green, M. Greaves, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Two unusual neurological presentations of granulocytic sarcoma in Philadelphia positive chronic myeloid leukaemia.

A. Green, R. Marcus, P. Mahendra, 1994, Leukemia & lymphoma.

A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

A. Green, T. Barbui, A. Bench, 2000, Hematology. American Society of Hematology. Education Program.

Adaptation to ex vivo culture drives human haematopoietic stem cell loss of repopulation capacity in a cell cycle independent manner

Emily F. Calderbank, E. Diamanti, E. Laurenti, 2022, bioRxiv.

ONCOLOGY Chromosomal deletions in haematological malignancies

A. Green, P. Micossi, W. Hillis, 1993, The Lancet.

Pathogenesis of polycythaemia vera.

A. Green, 1997, Lancet.

Pathogenesis of polycythaemia vera

A. Green, Anthony R. Green, 1996, The Lancet.

Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes.

A. Green, P. Fenaux, M. Scott, 1996, Blood.

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.

P. Campbell, H. Grallert, A. Green, 2010, Blood.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

J. D. van der Walt, P. Campbell, A. Green, 2005, The New England journal of medicine.

Notch Signaling Mediates Secondary Senescence

A. Green, N. Neretti, K. Kirschner, 2019, Cell reports.

Notch signalling mediates secondary senescence

A. Green, N. Neretti, K. Kirschner, 2019, bioRxiv.

Preparation and properties of silyl- and germyl-trifluoromethylacetylenes (1,1,1-trifluoro-4-silabut-2-yne and 1,1,1-trifluoro-4-germabut-2-yne), and molecular structure of silyltrifluoromethylacetylene determined by electron diffraction

A. Green, D. Rankin, A. Robiette, 1984 .

Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes

T. L. Hood, P. Deloukas, D. Bentley, 2000, Oncogene.

Retinoic acid and the differentiation of lymphohaemopoietic stem cells.

A. Green, B. Göttgens, 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

Life histories of myeloproliferative neoplasms inferred from phylogenies

P. Campbell, A. Menzies, A. Green, 2022, Nature.

Recessive mechanisms of malignancy.

A. Green, A. Green, 1988, British Journal of Cancer.

Transgenic Analysis of the Stem Cell Leukemia +19 Stem Cell Enhancer in Adult and Embryonic Hematopoietic and Endothelial Cells

B. Göttgens, A. Green, M. Socolovsky, 2005, Stem cells.

Central nervous system effects of hypothalamic hormones and other peptides R. Collu, A. Barbeau, J. K. Ducharme & J.-G. Rochefort (Eds). Raven Press, New York (1979). 435 pp., $45.50

A. Green, 1979, Neuroscience.

Changes in γ‐Aminobutyric Acid Biochemistry and Seizure Threshold

A. Green, 1986 .

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

P. Campbell, S. O'meara, J. Teague, 2018, The New England journal of medicine.

Transcriptional Regulation of the SCL Locus: Identification of an Enhancer That Targets the Primitive Erythroid Lineage In Vivo

A. Green, B. Gottgens, E. Delabesse, 2005, Molecular and Cellular Biology.

Combined Single-Cell Functional and Gene Expression Analysis Resolves Heterogeneity within Stem Cell Populations

Fabian J. Theis, Berthold Göttgens, Chris P. Ponting, 2015, Cell stem cell.

An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation.

P. Campbell, A. Green, G. Vassiliou, 2006, Haematologica.

Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation

C. Pecquet, S. Constantinescu, A. Green, 2014, Oncogene.

Transcriptional regulation of the stem cell leukemia gene (SCL)--comparative analysis of five vertebrate SCL loci.

Berthold Göttgens, Bjarne Knudsen, Jane Rogers, 2002, Genome research.

Analysis of vertebrate SCL loci identifies conserved enhancers

Berthold Göttgens, Sabine Bahn, D. Grafham, 2000, Nature Biotechnology.

Transcription factors, translocations and haematological malignancies.

A. Green, 1992, Blood reviews.

Rescue of the lethal scl(-/-) phenotype by the human SCL locus.

B. Göttgens, A. Green, A. Bench, 2002, Blood.

Regulation of the stem cell leukemia (SCL) gene: A tale of two fishes

Berthold Göttgens, James G. R. Gilbert, Roger Patient, 2001, Proceedings of the National Academy of Sciences of the United States of America.

High-resolution array-CGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer

Y. Wang, I. O. Ellis, S. Tavare, 2007 .

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells

Carlos Caldas, Fengtang Yang, Rosalind Eeles, 2015, Genome research.

Patterns of somatic structural variation in human cancer genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

B. Göttgens, J. Kutok, K. Akashi, 2005, Blood.

Notch mediates secondary senescence

A. Green, N. Neretti, K. Kirschner, 2019 .

Transcription factors in hematopoietic differentiation and leukemia

A. Green, M. Chapman, Michael Chapman, 2004 .

Genome-wide mutational signatures of immunological diversification in normal lymphocytes

G. Getz, P. Campbell, Mairi S. Shepherd, 2021, bioRxiv.

Identifying gene regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites.

Shane C. Dillon, P. Campbell, I. Dunham, 2006, Genome research.

The SCL gene: from case report to critical hematopoietic regulator.

A. Green, C. Begley, A R Green, 1999, Blood.

Lineage-restricted regulation of the murine SCL/TAL-1 promoter.

C. Begley, B. Göttgens, A. Green, 1995, Blood.

Structure of the gene encoding the murine SCL protein.

J. Visvader, A. Green, C. Begley, 1994, Gene.

Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes.

A. Green, N. White, E. Nacheva, 1994, Blood.

Comparative and functional analyses of LYL1 loci establish marsupial sequences as a model for phylogenetic footprinting.

Berthold Göttgens, Frank Grützner, Jane Rogers, 2003, Genomics.

Cytogenetics of the chronic myeloid leukemia-derived cell line K562: karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization.

S. Gribble, A. Green, I. Roberts, 2000, Cancer genetics and cytogenetics.

Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites.

B. Göttgens, A. Green, A. Bench, 1999, Developmental biology.

Transcriptional Regulation of the Stem Cell Leukemia Gene by PU.1 and Elf-1*

B. Göttgens, A. Green, M. Sánchez, 1998, The Journal of Biological Chemistry.

The SCL gene specifies haemangioblast development from early mesoderm

B. Göttgens, A. Green, M. Gering, 1998, The EMBO journal.

Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells.

B. Göttgens, A. Green, J. Landry, 2005, Blood.

Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development.

Berthold Göttgens, Noel Buckley, Anthony R Green, 2004, Human molecular genetics.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

P. Campbell, A. Green, J. Marsden, 2005, The Lancet.

The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress

E. Laurenti, D. Kent, A. Krešo, 2014, Nature.

a powerful and independent prognostic indicator in chronic myeloid leukemia

L. Campbell, A. Green, J. Szer, 2001 .

Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms

A. Green, J. Nangalia, J. Grinfeld, 2017, Haematologica.

Real-time PCR mapping of DNaseI-hypersensitive sites using a novel ligation-mediated amplification technique

Ludovic Vallier, Berthold Gottgens, A. Green, 2007, Nucleic acids research.

by Fli-1 and Elf-1 Bound Hematopoietic-Endothelial Enhancer Bifunctional ' of a 5 Required for Hematopoiesis: Identification +18/19 Stem Cell Enhancer Is Not scl The

B. Göttgens, A. Green, S. Kinston, 2014 .

Mapping and Functional Characterisation of a CTCF-Dependent Insulator Element at the 3′ Border of the Murine Scl Transcriptional Domain

Amy Chaney, B. Göttgens, A. Green, 2012, PloS one.

The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype.

B. Göttgens, V. Kouskoff, F. Sablitzky, 2007, Blood.

Analysis of multiple genomic sequence alignments: a web resource, online tools, and lessons learned from analysis of mammalian SCL loci.

Berthold Göttgens, Jane Rogers, Anthony R Green, 2004, Genome research.

29 – Transcriptional Regulation of Hematopoietic Stem Cells

B. Göttgens, A. Green, 2004 .

Manipulation of Mouse Hematopoietic Progenitors by Specific Retroviral Infection*

B. Göttgens, A. Green, A. Leavitt, 2003, Journal of Biological Chemistry.

Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells

E. Lander, T. Golub, S. Monti, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Distinct Mechanisms Direct SCL/tal-1 Expression in Erythroid Cells and CD34 Positive Primitive Myeloid Cells*

B. Göttgens, A. Green, A. Elefanty, 1997, The Journal of Biological Chemistry.

Discordant regulation of SCL/TAL-1 mRNA and protein during erythroid differentiation.

B. Göttgens, A. Green, A. Murrell, 1995, Oncogene.

Expression of lineage restricted transcription factors precedes lineage specific differentiation in a multipotent haemopoietic progenitor cell line.

A. Green, A. Murrell, T. Dexter, 1994, Oncogene.

The SCL protein displays cell-specific heterogeneity in size.

A. Green, C. Begley, N. Nicola, 1994, Leukemia.

Erythroid expression of the 'helix-loop-helix' gene, SCL.

A. Green, C. Begley, E. Salvaris, 1991, Oncogene.

Molecular cloning and chromosomal localization of the murine homolog of the human helix-loop-helix gene SCL.

J. Visvader, A. Green, C. Begley, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Transcription factors and the regulation of haemopoiesis: Lessons from GATA and SCL proteins

A. Green, A. Murrell, E. Bockamp, 1994, BioEssays : news and reviews in molecular, cellular and developmental biology.

The role of the stem cell leukemia (SCL) gene in hematopoietic and endothelial lineage specification.

B. Göttgens, A. Green, M. Sánchez, 2002, Journal of hematotherapy & stem cell research.

Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development

Berthold Göttgens, John E. Pimanda, Nicola K. Wilson, 2007, Proceedings of the National Academy of Sciences.

Philadelphia‐negative chronic myeloid leukaemia: detection by FISH of BCR‐ABL fusion gene localized either to chromosome 9 or chromosome 22

A. Green, E. Nacheva, D. Bloxham, 1994, British journal of haematology.

The SCL Gene: From Case Report to Critical Hematopoietic Regulator

A. Green, C. Begley, Begley Cg, 1999 .

RFP represses transcriptional activation by bHLH transcription factors

A. Green, B. Champion, P. Hayward, 2005, Oncogene.

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

7 Molecular genetics and cytogenetics of myeloproliferative disorders

A. Green, A. Bench, K. Champion, 1998 .

Appendix I: Normal Values

A. Green, D. Catovsky, A. Hoffbrand, 2010 .

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype

I. Ellis, J. Reis-Filho, A. Green, 2008, British Journal of Cancer.

Clonal dynamics of haematopoiesis across the human lifespan

Emily F. Calderbank, M. Stratton, P. Campbell, 2021, Nature.

Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.

Cameron S. Osborne, Nicola K. Wilson, P. Campbell, 2019, Blood.

Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.

A. Green, R. Zhao, G. Follows, 2008, The New England journal of medicine.

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer

I. Ellis, A. Green, E. Rakha, 2015, British Journal of Cancer.

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

P. Campbell, K. Döhner, H. Döhner, 2006, Blood.

Proviral position effects: possible probes for genes that suppress transcription.

A. Green, D. Gillespie, J. Wyke, 1989, Ciba Foundation symposium.

A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region.

P. Deloukas, D. Bentley, R. Gwilliam, 1998, Genomics.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

J. D. Fitzpatrick, J W Teague, P. Campbell, 2013, The New England journal of medicine.

Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.

Nicola K. Wilson, B. Göttgens, Mairi S. Shepherd, 2018, Blood.

Pathogenesis of Myeloproliferative Disorders.

A. Green, J. Nangalia, J. Grinfeld, 2016, Annual review of pathology.

Pathogenesis of Myeloproliferative Disorders Volume 11 of the Annual Review of Pathology: Mechanisms of Disease

A. Green, J. Nangalia, J. Grinfeld, 2015 .

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

P. Campbell, M. Griesshammer, A. Green, 2006, Blood.

The Molecular Basis of Leukaemia and Lymphoma

A. Green, G. Vassiliou, 2010 .

Comparative genomic hybridization in acute myeloid leukemia. A comparison with G-banding and chromosome painting.

A. Green, E. Nacheva, E. Nacheva, 1995, Cancer genetics and cytogenetics.

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions

Kirsten R. McEwen, P. Campbell, A. Green, 2013, Clinical Epigenetics.

Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies

P. Deloukas, A. Hunt, A. Green, 2004, British journal of haematology.

Suppression of the Neoplastic Phenotype

A. Green, J. Wyke, 1986 .

ANTI-ONCOGENES A Subset of Regulatory Genes Involved in Carcinogenesis?

A. Green, J. Wyke, 1985, The Lancet.

Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues

A. Green, T. Holyoake, R. Mesa, 2009, Leukemia.

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features

G. Daley, A. Green, W. Vainchenker, 2008, Leukemia.

The human CD40 gene lies within chromosome 20q deletions associated with myeloid malignancies

A. Green, E. Nacheva, F. Asimakopoulos, 1996, British journal of haematology.

LIF independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease

Andrew J. Bannister, B. Göttgens, J. Nichols, 2010, Nature Cell Biology.

Comparative genomic hybridization: a comparison with molecular and cytogenetic analysis.

D. Ledbetter, M. Bittner, A. Green, 1998, Cancer genetics and cytogenetics.

Analysis of Jak 2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation Short title : Cytokine signaling in developmental hematopoiesis

Kimber, Gillian, Katrin, 2016 .

JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation

D. Kent, J. Li, A. Green, 2015, Oncogene.

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.

D. Kent, A. Green, G. de Haan, 2014, Experimental hematology.

The Biological Influence of Mutation Order on Myeloproliferative Neoplasms *

Danai, D. Kent, K. Döhner, 2015 .

Cytokine‐induced megakaryocytic differentiation is regulated by genome‐wide loss of a uSTAT transcriptional program

B. Göttgens, A. Green, K. Kirschner, 2015, The EMBO journal.

cis-Regulatory Remodeling of the SCL Locus during Vertebrate Evolution

B. Göttgens, A. Green, G. Follows, 2010, Molecular and Cellular Biology.

Postgraduate Haematology: Hoffbrand/Postgraduate Haematology

A. Green, D. Catovsky, A. Hoffbrand, 2010 .

ECT — How does it work?

A. Green, 1978, Trends in Neurosciences.

Myeloproliferative neoplasms: from origins to outcomes.

A. Green, J. Nangalia, 2017, Hematology. American Society of Hematology. Education Program.

Myeloproliferative neoplasms: from origins to outcomes.

A. Green, J. Nangalia, 2017, Blood.

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

M. Malumbres, A. Green, C. Bock, 2016, Cancer cell.

Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women

I. Ellis, E. Rakha, A. Green, 2012, Breast Cancer Research and Treatment.

Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic.

I. Ellis, A. Green, K. Cheung, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre

I. Ellis, A. Green, A. Green, 2011, British Journal of Cancer.

Sonographic correlations with the new molecular classification of invasive breast cancer

I. O. Ellis, E. A. Rakha, I. Ellis, 2009, European Radiology.

The mammographic correlations of a new immunohistochemical classification of invasive breast cancer.

G. Ball, I. Ellis, E. Rakha, 2008, Clinical radiology.

Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up

I. Ellis, E. Rakha, S. Pinder, 2007, Journal of medical screening.

In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis.

Mark A. Hall, B. Göttgens, A. Green, 2004, Blood.

The novelty of our approach is to show that the order in which mutations are acquired influences tumor biology , the behavior of stem and progenitor cells , and clinical presentation

D. Kent, A. Green, D. M., 2015 .

Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer

I. Ellis, E. Rakha, A. Green, 2016, Breast Cancer Research and Treatment.

Guideline for the diagnosis and management of myelofibrosis

A. Mead, A. Green, R. Mesa, 2012, British journal of haematology.

Chromosomal deletions in haematological malignancies.

A. Green, 1993, Lancet.

Genomic imbalances in CML blast crisis: 8q24.12–q24.13 Segment identified as a common region of over‐representation

S. Gribble, A. Green, I. Roberts, 2003, Genes, chromosomes & cancer.

Molecular cytogenetics of polycythaemia vera: lack of occult rearrangements detectable by 20q LSP screening, CGH, and M-FISH

A. Green, A. Bench, E. Nacheva, 2003, Leukemia.

Calpain system protein expression in basal-like and triple-negative invasive breast cancer

I. Ellis, A. Green, R. Macmillan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

STAT1 is essential for HSC function and maintains MHCIIhi stem cells that resist myeloablation and neoplastic expansion

Nicola K. Wilson, E. Laurenti, N. Wilson, 2022, Blood.

Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis

A. Green, C. Watson, S. Pensa, 2011, Cell Death and Differentiation.

Analyses of the extent of shared synteny and conserved gene orders between the genome of Fugu rubripes and human 20q.

Thomas Haaf, Anthony R Green, Sarah F. Smith, 2002, Genome research.

Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.

I. Ellis, E. Rakha, A. Green, 2014, Pathology, research and practice.

Tdr2, a new zebrafish transposon of the Tc1 family.

D. Grafham, B. Göttgens, A. Green, 1999, Gene.

Proliferation Drives Aging-Related Functional Decline in a Subpopulation of the Hematopoietic Stem Cell Compartment

D. Kent, I. Macaulay, M. Hemberg, 2017, Cell reports.

P4-09-11: Kinesin Family Member 2C (KIF2C) Is a New Surrogate Prognostic Marker in Breast Cancer (BC).

I. O. Ellis, Christophe Lemetre, I. Ellis, 2011 .

Helix-loop-helix protein inhibitor of differentiation 4 (ID4) expression is an indicator of poor survival in Nigerian breast cancer women

I. Ellis, E. Rakha, A. Green, 2014 .

Tumour cell membrane laminin expression is associated with basal-like phenotype and poor survival in Nigerian breast cancer.

I. Ellis, E. Rakha, A. Green, 2016, The Malaysian journal of pathology.

Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer

G. Ball, I. Ellis, C. Caldas, 2012, Breast Cancer Research and Treatment.

Mutation and methylation analysis of the transforming growth factor β receptor II gene in polycythaemia vera

A. Green, A. Bench, B. Huntly, 2001, British journal of haematology.

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia

Gabriela Alexe, Tobias Berg, Hanibal Bohnenberger, 2017, Cancer cell.

Impaired In Vitro Erythropoiesis following Deletion of the Scl (Tal1) +40 Enhancer Is Largely Compensated for In Vivo despite a Significant Reduction in Expression

B. Göttgens, A. Green, Andrew Dimond, 2013, Molecular and Cellular Biology.

Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray

Mike Scott, Michael J Keating, Larissa Belov, 2006, British journal of haematology.

Multiplexing for Oxidative Bisulfite Sequencing (oxBS-seq).

A. Green, K. Kirschner, Tamir Chandra, 2018, Methods in molecular biology.

Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms.

A. Green, E. Bresnick, Puwen Tan, 2021, Cell stem cell.

Clonal approaches to understanding the impact of mutations on hematologic disease development.

A. Green, J. Nangalia, Emily Mitchell, 2019, Blood.

JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response

A. Green, A. Godfrey, H. Park, 2014, Proceedings of the National Academy of Sciences.

DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype

Peter J Campbell, David C Wedge, Anthony R Green, 2015, Haematologica.

Molecular genetics and cytogenetics of myeloproliferative disorders.

A. Green, A. Bench, K. Champion, 1998, Bailliere's clinical haematology.

The Medical Research Council PT1 Trial in Essential Thrombocythemia.

P. Campbell, A. Green, J. Reilly, 2004 .

Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia

P. Campbell, Mairi S. Shepherd, D. Kent, 2020, HemaSphere.

Management of the myeloproliferative disorders : distinguishing data from dogma.

P. Campbell, A. Green, G. Vassiliou, 2004, The Hematology Journal.

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

P. Campbell, A. Green, P. Beer, 2010, Haematologica.

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones

A. Green, W. Erber, A. Bench, 2009, British journal of haematology.

The long-term outlook for essential thrombocythemia.

P. Campbell, A. Green, 2006, Mayo Clinic proceedings.

Hydroxycarbamide plus Aspirin vs Aspirin Alone in Patients with Essential Thrombocythaemia Aged 40-59 Years Without High-Risk Features

P. Campbell, A. Green, C. Harrison, 2018 .

Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms

P. Campbell, A. Menzies, A. Green, 2020 .

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2017, bioRxiv.

Transcriptional Link between Blood and Bone: the Stem Cell Leukemia Gene and Its +19 Stem Cell Enhancer Are Active in Bone Cells

B. Göttgens, A. Green, Lev Silberstein, 2006, Molecular and Cellular Biology.

Population dynamics of normal human blood inferred from somatic mutations

M. Stratton, P. Campbell, Mairi S. Shepherd, 2018, Nature.

Sex differences in oncogenic mutational processes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2019, Nature Communications.

Three dimensional reconstruction of a human breast carcinoma using routine laboratory equipment and immunohistochemistry

I. Ellis, E. Rakha, A. Green, 2005, Journal of Clinical Pathology.

Adaptation to ex vivo culture drives human haematopoietic stem cell loss of repopulation capacity in a cell cycle independent manner

Nicola K. Wilson, Emily F. Calderbank, E. Diamanti, 2023, bioRxiv.

The transcription factors Scl and Lmo2 act together during development of the hemangioblast in zebrafish.

A. Green, S. Ekker, C. Verfaillie, 2007, Blood.

hematopoietic stem cells significantly contribute to adult hematopoiesis In vivo fate tracing studies using the SCL stem cell enhancer: embryonic

A. Green, C. Begley, D. Izon, 2013 .

Pharmacology and Biochemistry of Psychiatric Disorders

A. Green, D. Costain, 1981 .

Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling

E. Colado, C. López-Otín, J. Freije, 2015, Nature Medicine.

Regulation of lineage restricted haemopoietic transcription factors in cell hybrids.

A. Green, A. Murrell, 1995, Oncogene.

Three-dimensional reconstruction of sentinel lymph nodes with metastatic breast cancer indicates three distinct patterns of tumour growth

I. Ellis, E. Rakha, A. Green, 2009, Journal of Clinical Pathology.

Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray

I. Ellis, A. Green, K. Cheung, 2020, Breast Cancer Research and Treatment.

Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms

A. Green, E. Bresnick, Puwen Tan, 2021, Cell stem cell.

Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer.

B. Göttgens, A. Green, J. Pimanda, 2006, Blood.

The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera

B. Göttgens, A. Green, D. Fearon, 1997, Oncogene.

Clonal Dynamics of Normal Haematopoiesis with Human Ageing

Emily F. Calderbank, M. Stratton, E. Laurenti, 2021, Blood.

Life histories of myeloproliferative neoplasms inferred from phylogenies

A. Menzies, A. Green, L. Moore, 2022, Nature.

Some perpendicular bands of silyl and germyl acetylenes MH3CCR

A. Green, J. Duncan, S. Cradock, 1979 .

Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera.

A. Green, T. Pearson, M. Aldred, 1996, Blood.

Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients.

I. Ellis, A. Green, K. Cheung, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Appendix II: World Health Organization Classification of Tumours of the Haematopoietic and Lymphoid Tissues

A. Green, D. Catovsky, A. Hoffbrand, 2010 .

Management of polycythemia vera and essential thrombocythemia.

P. Campbell, A. Green, Anthony R. Green, 2005, Hematology. American Society of Hematology. Education Program.

Supplementary file 1.

Jack A. Taylor, M. Stratton, D. Hayes, 2011 .

HIF-2alpha Associated Familial Erythrocytosis Supports the PHD2-HIF- 2alpha-VHL Axis as the Major Regulator of Erythropoietin Production

A. Green, D. Oscier, M. McMullin, 2008 .

Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?

P. Campbell, D. Kent, E. Papaemmanuil, 2014, Blood.

Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia.

L. Campbell, A. Green, D. Niederwieser, 2002, Blood.

chronic myeloid leukemia translocation and provide a powerful and independent prognostic indicator in Deletions of the derivative chromosome 9 occur at the time of the Philadelphia

L. Campbell, A. Green, A. Bench, 2008 .

Oncogenic hypophosphataemia and ectopic corticotrophin secretion due to oat cell carcinoma of the trachea.

A. Green, I. MacFarlane, C. van Heyningen, 1994, Journal of clinical pathology.

Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis

P. Campbell, T. Pearson, M. Polkey, 2005, British journal of haematology.

Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms

A. Green, E. Baxter, C. Harrison, 2023, Nature Cancer.

Supplementary file 3.

Jack A. Taylor, M. Stratton, D. Hayes, 2014 .

Myeloproliferative disorders.

A. Green, A. Bench, N. Cross, 2001, Best practice & research. Clinical haematology.

Comparative Genomic Hybridization: A Comparison with Molecular and Cytogenetic Analysis

D. Ledbetter, M. Bittner, A. Green, 1998 .

SC3 - consensus clustering of single-cell RNA-Seq data

Mauricio Barahona, Michael T. Schaub, Martin Hemberg, 2016, Nature Methods.

Supplementary file 2.

Jack A. Taylor, D. Hayes, P. Futreal, 2014 .

Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium.

Mark A. Hall, B. Göttgens, A. Green, 2004, Blood.

Chapter 4 Human hematopoietic stem cell integrity is guarded by the Unfolded Protein Response

E. Laurenti, D. Kent, A. Krešo, 2014 .

Supplementary file 1.

Jack A. Taylor, D. Hayes, P. Futreal, 2014 .

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Nuno A. Fonseca, Benjamin J. Raphael, Allison P. Heath, 2020, Nature Communications.

Disease heterogeneity and personalized prognosis in myeloproliferative neoplasms

P. Campbell, S. O'meara, J. Teague, 2018 .

The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations

P. Campbell, A. Green, S. Schnittger, 2009 .

Genome-wide Analysis of Simultaneous GATA 1 / 2 , RUNX 1 , FLI 1 , and SCL Binding in Megakaryocytes Identifies Hematopoietic Regulators

W. Ouwehand, B. Göttgens, N. Wilson, 2011 .

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas

Jack A. Taylor, D. Hayes, P. Futreal, 2013, Gut.

A tale of two lineages: the origins of blood and endothelium

A. Green, 2005 .

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Carlos Caldas, Fengtang Yang, Rosalind Eeles, 2016, Genome research.

chromosome 9 in chronic myeloid leukemia Double jeopardy from a single translocation : deletions of the derivative

A. Green, A. Bench, B. Huntly, 2003 .

Clinical outcome of triple-negative primary breast cancer in older women: Comparison with their younger counterparts.

I. Ellis, A. Green, K. Cheung, 2011, Journal of Clinical Oncology.

Supplementary file 1.

Jack A. Taylor, D. Hayes, P. Futreal, 2011 .

Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development.

B. Göttgens, A. Green, J. Landry, 2005, Human molecular genetics.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

P. Campbell, A. Green, G. Vassiliou, 2005, The Lancet.

Genotype-phenotype interactions in the myeloproliferative neoplasms.

A. Green, A. Godfrey, 2012, Hematology/oncology clinics of North America.

JAK2 V617F Mutation Identifies a Biologically Distinct Subtype of Essential Thrombocythemia Which Resembles Polycythemia Vera.

P. Campbell, A. Green, J. Marsden, 2005 .

Supplementary File 4

Jack A. Taylor, D. Hayes, P. Futreal, 2014 .

MPN-associated myelofibrosis (MPN-MF).

A. Green, S. Verstovsek, R. Gale, 2011, Leukemia research.

Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.

A. Green, D. Oscier, M. McMullin, 2008, Blood.

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

B. Göttgens, J. Kutok, K. Akashi, 2005, Blood.

studies, cytogenetic associations, and role in leukemic transformation in the myeloproliferative disorders: timing, clonality JAK2 Mutation of

P. Campbell, A. Green, W. Erber, 2010 .

DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype

P. Campbell, D. Wedge, A. Green, 2015, Haematologica.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells

Fengtang Yang, A. Børresen-Dale, M. Stratton, 2015, Genome research.

Essential thrombocythemia.

A. Green, M. Ingelmo, J. Villalta, 2003, Hematology/oncology clinics of North America.

Supplementary File 4

Jack A. Taylor, D. Hayes, P. Futreal, 2014 .

Guideline for investigation and management of adults and children presenting with a thrombocytosis

P. Campbell, A. Green, W. Erber, 2010, British journal of haematology.

HORMONE CONTROL OF BREAST CANCER

A. Green, 1961 .